CD274 and lung carcinoma: PCD1/PD-L1 drugs are approved by FDA for the therapy of lung cancer (Nivolumab, Pembrolizumab, Atezolizumab, and Durvalumab), and their efficacy in treatment is shown in different clinical trials.33